PMID- 36303832
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221029
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - A systemic review of taxanes and their side effects in metastatic breast cancer.
PG  - 940239
LID - 10.3389/fonc.2022.940239 [doi]
LID - 940239
AB  - Taxanes-containing chemotherapy constitutes an essential backbone for both early 
      and metastatic breast cancer (mBC). However, the two major taxane 
      drugs-paclitaxel and docetaxel-have distinct safety profiles. In this review, we 
      summarize the safety outcome and management following treatment with both taxanes 
      from selected clinical trials. We utilized PubMed to perform literature search 
      before April 2021. Five phase III randomized controlled trials with reports of 
      individual taxane adverse events (AEs) were included in this review. Grade 3/4 
      AEs were summarized and discussed extensively. The rates of grade 3/4 neutropenia 
      were higher with docetaxel than with paclitaxel. For non-hematologic grade 3/4 
      AEs, peripheral neuropathy was more frequent with paclitaxel while fluid 
      retention was more frequent with docetaxel. Compared to paclitaxel, docetaxel had 
      a higher rate of grade 3/4 gastrointestinal AEs. Grade 3/4 myalgia were generally 
      comparable between the two taxanes. Except for neutropenia, the incidence rate of 
      grade 3/4 AEs of taxanes was generally manageable. Peripheral neuropathy was more 
      common with paclitaxel while grade 3/4 neutropenia was more common with 
      docetaxel.
CI  - Copyright (c) 2022 Lai, Chao, Liu, Huang and Tseng.
FAU - Lai, Jiun-I
AU  - Lai JI
AD  - Division of Medical Oncology, Department of Oncology, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
AD  - Center of Immuno-Oncology, Department of Oncology, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
AD  - Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung 
      University, Taipei, Taiwan.
FAU - Chao, Ta-Chung
AU  - Chao TC
AD  - Division of Medical Oncology, Department of Oncology, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
AD  - Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
AD  - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung 
      University, Taipei, Taiwan.
FAU - Liu, Chun-Yu
AU  - Liu CY
AD  - Division of Medical Oncology, Department of Oncology, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
AD  - Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
AD  - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung 
      University, Taipei, Taiwan.
AD  - Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
FAU - Huang, Chi-Cheng
AU  - Huang CC
AD  - Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
AD  - Division of Experimental Surgery, Department of Surgery, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
AD  - School of Public Health, College of Public Health, National Taiwan University, 
      Taipei, Taiwan.
FAU - Tseng, Ling-Ming
AU  - Tseng LM
AD  - Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
AD  - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung 
      University, Taipei, Taiwan.
AD  - Division of Experimental Surgery, Department of Surgery, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
AD  - Division of General Surgery, Department of Surgery, Taipei Veterans General 
      Hospital, Taipei, Taiwan.
LA  - eng
PT  - Systematic Review
DEP - 20221011
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9592970
OTO - NOTNLM
OT  - adverse event
OT  - breast cancer
OT  - docetaxel
OT  - paclitaxel
OT  - systemic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/29 06:00
MHDA- 2022/10/29 06:01
PMCR- 2022/01/01
CRDT- 2022/10/28 02:38
PHST- 2022/05/10 00:00 [received]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/10/28 02:38 [entrez]
PHST- 2022/10/29 06:00 [pubmed]
PHST- 2022/10/29 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.940239 [doi]
PST - epublish
SO  - Front Oncol. 2022 Oct 11;12:940239. doi: 10.3389/fonc.2022.940239. eCollection 
      2022.